# Seaport Therapeutics Inc. (SPTX) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $24.86, market value $1.3 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Seaport Therapeutics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 3.1×**. The shares trade at 3.1× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -6.2%**. Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: 80.9%**. A 80.9% return on equity is extremely high; check whether buybacks or debt have shrunk the equity base, which flatters the ratio.

## Growth
- **EPS growth (1 yr): -59.9%**. Earnings per share fell 59.9%.

## Financial health
- **Current ratio: 17.46** (quick 17.46). Current assets cover the next year's liabilities 17.46 times.
- **Piotroski F-score: 1/9**. 1 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Seaport Therapeutics Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (6 analysts). 6 analysts cover Seaport Therapeutics Inc.; the consensus is strong_buy, with an average price target of $37.00 (+49% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **From 52-week high: -12.4%** (67.4% above the low). Trading 12% below its 52-week high.
- **RSI (14-day): 56**. An RSI of 56 is neutral.
- **Beta (1 yr): 0.97** (volatility 75%). Beta of 0.97 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=SPTX · Page: https://foliofundamentals.com/stocks/sptx

Not investment advice.